Company Overview

Cibus, Inc. is an agricultural biotechnology company focused on developing and commercializing gene‑edited crop traits to improve productivity, sustainability, and resilience in global agriculture. The company operates within the agricultural biotechnology and crop science industries, applying proprietary gene‑editing technologies to enhance traits such as herbicide tolerance, disease resistance, and yield performance. Its primary revenue drivers are research collaborations, licensing agreements, and the development of commercial seed traits intended for large‑scale agricultural markets.

Founded in 2001, Cibus evolved from a research‑oriented biotechnology firm into a publicly traded company through a business combination with Calyxt, Inc. in 2023, after which the combined entity adopted the Cibus name and the CBUS ticker symbol. The company positions itself as a provider of non‑transgenic, gene‑edited solutions designed to meet regulatory frameworks in multiple jurisdictions, which it views as a strategic advantage in accelerating market adoption.

Business Operations

Cibus conducts operations primarily through its gene‑edited trait development business, which focuses on applying its Rapid Trait Development System (RTDS®) to commercial crops. The company generates value by developing proprietary traits that are either licensed to seed companies or advanced through partnerships toward commercialization. Its core crop focus areas include oilseeds, grains, and specialty crops, with particular emphasis on canola/rapeseed and rice.

Operations span both domestic and international activities, with research and development capabilities in the United States and collaborations extending to global agricultural markets. Through its acquisition of Calyxt, Inc., Cibus obtained additional intellectual property, plant breeding assets, and operational infrastructure that support its commercialization strategy. The company does not currently operate large‑scale manufacturing but relies on partnerships and licensees for seed multiplication and distribution.

Strategic Position & Investments

Cibus’s strategic direction centers on scaling its gene‑edited trait pipeline and expanding partnerships with major seed and agribusiness companies. Growth initiatives include advancing late‑stage herbicide tolerance traits, broadening crop coverage, and pursuing regulatory approvals in key agricultural markets. The company emphasizes traits that can be rapidly adopted without transgenic classification in certain regions, which it believes reduces time to market.

The acquisition of Calyxt, Inc. represents Cibus’s most significant recent investment, consolidating complementary technologies and public company infrastructure. Cibus continues to invest in emerging gene‑editing applications and trait discovery programs aimed at addressing climate resilience and sustainable farming practices. Data inconclusive based on available public sources regarding any additional material acquisitions or equity investments beyond this transaction.

Geographic Footprint

Cibus is headquartered in North America, with its principal executive offices in the United States. The company maintains a presence across North America and Europe, primarily through research activities, regulatory engagement, and commercial partnerships. Its geographic strategy focuses on regions with large-scale production of its target crops and supportive regulatory environments for gene‑edited technologies.

Internationally, Cibus’s influence is driven more by intellectual property, licensing, and collaborative agreements than by owned physical infrastructure. The company targets global agricultural markets, including Europe, Asia‑Pacific, and Latin America, where demand for yield‑enhancing and sustainable crop traits is significant, though direct operational footprints in some regions remain limited.

Leadership & Governance

Cibus is led by a management team with experience in agricultural biotechnology, plant science, and commercialization. The leadership emphasizes scientific rigor, regulatory alignment, and partnership‑driven growth as core elements of its strategic vision. Governance follows public company standards established after its transition to a publicly listed entity.

Key executives include:

• Rory Riggs – Chief Executive Officer
• Peter Beetham – Chief Scientific Officer

Data inconclusive based on available public sources regarding additional executive appointments beyond these roles that can be independently verified across multiple reputable disclosures without ambiguity.